ICU antibiotic dosing: what really matters?
NCT ID NCT05352997
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 156 critically ill patients to find out what factors help achieve the right levels of beta-lactam antibiotics in the blood. Researchers collected clinical data and used therapeutic drug monitoring to see which patients reached target concentrations. The goal is to improve dosing for severe infections in intensive care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- beta-lactam antibiotics
- What this could lead to
- If successful, this could help doctors better dose beta-lactam antibiotics in intensive care, potentially improving infection treatment.
- What could go wrong
- This is a small, retrospective study that only observes past data, so it cannot prove cause and effect. Results may not apply to all patients or hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Leftover blood samples could unlock new medical discoveries
- La reunion health survey aims to uncover hidden disease patterns
- Hunting the genes that make severe infections worse
- Aging immune system under the microscope: study seeks clues to infection risk in seniors
- New DNA test could revolutionize diagnosis of eye infections
- New mRNA vaccine aims to shield older adults from RSV